The US FDA aims to use Biovista's new technology platform as part of its Safe Use Initiative.
- PDF / 136,301 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 56 Downloads / 182 Views
1
■ The US FDA aims to use Biovista’s new technology platform as part of its Safe Use Initiative. Biovista’s Adverse Event Analysis (AEA) technology platform cross-correlates over 8000 diseases and 12 000 known adverse events against any target, drug or combination. It enables researchers to link preclinical data directly with potential clinical outcomes and explore possible risks of adverse events from a mechanistic perspective. The FDA has licensed the technology, and researchers from the FDA’s Center for Drug Evaluation and Research (CDER) Office of Clinical Pharmacology will collaborate with Biovista to test the use of this technology to help the FDA reduce the risks associated with certain mediations and help improve how healthcare providers go about selecting the drugs they prescribe. Biovista Inc. Biovista Inc. and FDA to Collaborate on a Medication Safety Initiative. Media Release : 13 Jan 2010. Available from: URL: http:// 809108623 www.biovista.com
0114-9954/10/1285-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 23 Jan 2010 No. 1285
Data Loading...
